Innovation Powered by

A discovery becomes useful when it reaches the people who need it. That journey takes more than a promising result: it requires testing, intellec
A University of Utah-developed technology is making headlines nationwide, demonstrating how groundbreaking research can move beyond the lab to ch
The University of Utah ranks among the top 10 U.S. universities in several key research commercialization measures, based on data from the AUTM 2
A discovery becomes useful when it reaches the people who need it. That journey takes more than a promising result: it requires testing, intellectual property protection, partnerships and a practical route to adoption.
The 2026 University of Utah Innovation Awards recognize researchers, students and entrepreneurs doing that work. Their achievements span licensed technologies, clinical development, industrial processes and emerging companies. For the Technology Licensing Office, they illustrate how research can become a foundation for better patient care, stronger industries and new businesses.
Meet this year’s recipients and watch their video spotlights below.
Fluidx has taken biomaterials research led by U co-founder Russell Stewart into a clinical-stage medical device company. Its gel embolic platform is designed to help physicians block blood flow during minimally invasive procedures. The company holds active licenses to nearly ten university technologies, building a business around protected U inventions.
In 2026, Fluidx completed enrollment in a multinational pivotal trial of its GPX Embolic Device involving 114 patients at 18 sites. The study met its primary safety and effectiveness endpoints, marking a significant step in the technology’s clinical development.
Minna Roh-Johnson and Dan Greiner co-founded CaLycia Bioscience to turn discoveries about macrophages into potential cancer treatments. Their engineered immune cells are designed to enter solid tumors and attack cancer cells, including those remaining after brain tumor surgery.
The founders have built preclinical evidence in melanoma and glioblastoma models and raised $400,000 in pre-seed funding. Their progress connects fundamental work on cell behavior with the scientific validation and company development needed to advance a new therapeutic approach.
Zak Fang’s career demonstrates how materials research can reshape manufacturing. His Hydrogen-Assisted Magnesiothermic Reduction, or HAMR, process offers an alternative route to titanium production, with potential reductions in energy use and cost. Commercialized by IperionX, the technology has helped catalyze more than $200 million in investment.
Fang’s contributions also extend to titanium alloy processing, powders for additive manufacturing and tungsten carbide tools. With more than 60 U.S. patents and two startup companies, he has repeatedly connected laboratory advances with industrial production and commercial opportunity.
Ravi Chandran is advancing niobium-based alloys for components that must withstand extreme heat and mechanical stress. His work through an ARPA-E-supported research program produced three inventions covering new alloy compositions and manufacturing approaches, with U.S. and international patent applications being pursued through the Technology Licensing Office.
Chandran has initiated discussions with materials and aerospace companies to explore licensing opportunities while pursuing support for scale-up. That work addresses a central challenge in technology transfer: moving promising material properties toward processes and components industry can use.
Robin Shaw’s research on cardiac bridging integrator 1, or cBIN1, has created a potential strategy for repairing defects within failing heart muscle cells. The university exclusively licensed the gene therapy technology to TikkunLev Therapeutics, which Shaw co-founded.
The partnership included a multi-million-dollar sponsored research commitment supporting studies needed before clinical testing. With results in large-animal models and a first-in-human study design, the program demonstrates a sustained progression from biological discovery to protected intellectual property and therapeutic development.
Jessica Swanson is developing a bioreactor that uses methane-eating microbes to address industrial emissions. Working with the U’s Energy Accelerator, she has conducted customer discovery across dairy, oil and gas, and coal to understand operational needs and identify commercial applications.
She also brought in reactor engineering expertise to strengthen the technology’s development. Her next steps include company formation, an STTR funding application and future patent protection as the technology matures. The effort shows how market insight can help shape a research program’s route to deployment.
Jeff Rosenbluth’s work brings innovation into the daily lives of people with complex physical conditions. His leadership in rehabilitation connects clinicians, researchers, caregivers and patients around practical needs, with independence and quality of life guiding the development of new approaches to care.
His impact illustrates another dimension of translation: creating the collaborations and care environments that help solutions reach the people they are intended to serve. By linking clinical expertise with patient experience, Rosenbluth helps turn ideas for better rehabilitation into changes in how care is delivered.
Evan Marsh is developing a point-of-care diagnostic for eosinophilic chronic rhinosinusitis using a nasal swab and rapid color-based readout. Co-designed with a practicing rhinologist, the platform aims to support objective diagnosis and monitoring over time.
Marsh paired the research with NSF I-Corps customer discovery to evaluate clinical need and commercial potential. His leadership in Bench to Bedside also helps other student teams navigate medical technology development, extending his contribution beyond his own diagnostic work.
At the Center for Medical Innovation, Lincoln Wagner has moved clinical concepts through design, prototyping and refinement. His work includes redesigning a cervical traction robot and developing two spinal positioning methods incorporated into the device and filed for patent protection.
He also helped turn a suction device concept into a functioning prototype, addressing mechanical and fluid-dynamics challenges. These projects demonstrate the practical engineering work required to advance medical inventions toward use, while giving an undergraduate meaningful responsibility in technology development.
Lontra Bio is commercializing synthetic antifreeze and mucin-inspired materials developed through U biomaterials research. Co-founder Rachel Detwiler has built collaborations across agriculture, cryopreservation, therapeutics and women’s health to explore applications and validate the technologies.
Her commercialization work includes 42 customer discovery interviews and an Ascender-supported effort involving production scale-up, formulation optimization and early product testing. Together, those activities help connect promising chemistry with customer requirements and future licensing opportunities.
Founded by computer science students Dante Suzuki and Haley Young, Autona develops software to automate manual tasks in biomedical research laboratories, including workflows involving images and video.
Through Lassonde DevLab, Suzuki has worked to build a company around those recurring research needs. Autona reflects a complementary route to translational impact: developing tools that can make research workflows more efficient, so laboratories can devote more time to interpreting results and pursuing new discoveries.
These recipients show the many steps between a research insight and a useful solution. Licensing agreements, prototypes, customer conversations and clinical studies each help establish whether an invention can deliver value beyond the university.
Have a discovery with potential for broader use? Connect with the Technology Licensing Office to explore intellectual property protection, commercialization resources and opportunities to work with industry.
A University of Utah-developed technology is making headlines nationwide, demonstrating how groundbreaking research can move beyond the lab to change lives.
NBC News recently spotlighted the University of Utah's revolutionary bionic arm, showcasing technology that allows people with limb loss to control a prosthetic with their thoughts—and even regain a sense of touch.
The segment follows Avi Davidson, the first participant to take the technology home for daily use as part of a clinical trial. From preparing meals to holding his wife's hand and feeling her touch, Davidson's experience offers a powerful look at the human impact of U Innovation.
Watch the NBC News segment on YouTube
The NBC feature is the latest in a series of high-profile media appearances for the technology.
In February 2025, the bionic arm was featured during FOX's Super Bowl LIX pregame broadcast, appearing in a segment narrated by Brad Pitt celebrating American ingenuity and innovation.
More recently, Utah Business and Deseret News highlighted the technology's progress toward everyday use. The latest NBC coverage builds on that momentum, bringing the innovation—and the people whose lives it could transform—to an even wider national audience.
Developed through years of research led by University of Utah professor Jacob George and the Utah NeuroRobotics Lab, the technology uses artificial intelligence and a direct nerve interface to translate neural signals into movement and restore sensory feedback.
In 2022, the university licensed the technology to spinout company Biologic Input Output Systems (BIOS), helping advance its path toward commercialization. Today, the first at-home clinical trial marks another important step toward making the technology accessible to more people.
The growing recognition also reflects the University of Utah's position as a national leader in research commercialization. According to the AUTM 2025 Annual Survey, the U ranks among the top 10 U.S. universities in five key commercialization measures, including invention disclosures, licensing agreements and newly licensed technologies.
The bionic arm is a compelling example of what that leadership looks like in practice: groundbreaking university research translated into technology with the potential to improve lives worldwide.
Read the full story about the bionic arm's first at-home trial on @theU.
The University of Utah ranks among the top 10 U.S. universities in several key research commercialization measures, based on data from the AUTM 2025 Annual Survey.
Research commercialization moves discoveries beyond the lab and into the world through products, treatments, services, licenses, and startups. The U’s performance is especially notable because it is achieving results comparable to larger research institutions while operating with a smaller research expenditure base, a sign of the strength and efficiency of Utah’s innovation ecosystem.
The U placed among the nation’s leaders in five key measures:
The survey results highlight both the U’s current performance and its potential for continued growth. The university’s research enterprise is expanding, creating a larger pipeline of discoveries with the potential to reach the marketplace and benefit the public.
As research activity grows, it can generate more ideas, invention disclosures, partnerships, licenses, and startups—strengthening the U’s ability to shape industries and improve lives.
“These benchmarks reflect the strength of the University of Utah’s innovation ecosystem and the faculty, researchers, and partners who help move discoveries toward real-world impact,” said Jason Young, senior director of commercialization.
The AUTM survey results add to a series of national recognitions for the University of Utah’s innovation ecosystem. The U has also recently been named among the top 100 universities globally for U.S. utility patents, No. 1 for producing unicorn founders, and recognized as one of the nation’s top universities for biomedical innovation. Together, these distinctions reflect growing momentum across the university’s innovation pipeline.
That impact can be seen in examples from the past year:
For faculty and researchers, the results point to more opportunities to translate discoveries into practical applications. For industry partners and investors, they signal access to a strong environment for bringing research discoveries to market. For the state, they demonstrate the University of Utah’s growing role in building Utah’s innovation economy.
As the U’s research enterprise expands, so does its capacity to turn discovery into public benefit, economic growth, and solutions to pressing challenges. The 2025 AUTM survey results show that the university’s commercialization efforts are already performing at a national level—and are positioned to make an even greater impact in the years ahead.
Wherever you are on your innovation journey, the Technology Licensing Office is your go-to source to connect you with the U’s innovation ecosystem.
Call 801.581.7792 or send us a message
Technology Licensing Office
303 Chipeta Way, #14. SLC, UT 84108
801-581-7792

Thank you for your interest in submitting a disclosure. Our disclosure portal is currently accessible only to university faculty members. If you are not a faculty member, please reach out to us directly. If your invention involves collaboration with a University of Utah employee, we encourage them to submit the disclosure on behalf of your team.
For further assistance, feel free to contact us at